# Moderna surpassed Wall Street estimates for first-quarter revenue.

*biotech · news · 2026-05-01 · MarketScreener*

## Key points

- Moderna's international COVID-19 vaccine revenue was $311 million, significantly surpassing U.S. revenue of $78 million.
- U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. have reduced domestic vaccine use.
- Moderna's FDA application for its mRNA-based flu vaccine has progressed after resolving a trial design dispute.
- Late-stage data for Moderna's norovirus and individualized cancer vaccines are expected soon.
- Moderna paid $2.22 per share in charges to settle a patent dispute over lipid nanoparticle technology.

**Companies:** Moderna
**Countries:** United States, United Kingdom, Canada, Australia

[Read the full story on MarketScreener](https://www.marketscreener.com/news/moderna-tops-quarterly-revenue-estimates-on-stronger-international-covid-vaccine-sales-ce7f58d9db8af022)

---

Canonical: https://newsio.io/n/7da7f82c-6a91-40b6-a0c4-72651916b96c/moderna-surpassed-wall-street-estimates-for-first-quarter-revenue-better-than-ex
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works